FDA reopens comment period
This article was originally published in The Tan Sheet
Executive Summary
FDA will reopen until May 18 the comment period on issues relating to its regulations for chemistry, manufacturing and controls supplements and other changes to approved marketing applications for human drugs, according to a Federal Register notice slated for publication April 16. The agency conducted a public meeting in February to consider comments on issues it should consider in revising those regulations, as required by the FDA Modernization Act of 1997 (1"The Tan Sheet" Feb. 26, 2007, p. 12)...
You may also be interested in...
FDA Urged To Revise Manufacturing Reg To Increase Flexibility For OTCs
Drug firms have more flexibility changing production protocols for over-the-counter drugs than pharmaceuticals, but the industry would benefit if FDA regulations allowed supplements for OTC products' chemistry, manufacturing and controls to be done without prior approval, an industry representative says
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.